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Abstract
For many anticancer therapies, it would be desirable to
accurately monitor and quantify tumor response early in
the treatment regimen. This would allow oncologists to
continue effective therapies or discontinue ineffective
therapies early in the course of treatment, and hence,
reduce morbidity. This is especially true for second- line
therapies, which have reduced response rates and
increased toxicities. Previous works by others and
ourselves have shown that water mobility, measured
by diffusion-weighted magnetic resonance imaging
(DW-MRI ), increases early in tumors destined to
respond to therapies. In the current communication,
we further characterize the utility of DW-MRI to predict
response of prostate cancer xenografts to docetaxel in
SCID mice in a preclinical setting. The current data
illustrate that tumor volumes and secreted prostate-
specific antigen both respond strongly to docetaxel in a
dose-responsive manner, and the apparent diffusion
coefficient of water (ADCw) increases significantly by 2
days even at the lowest doses (10 mg/kg). The ADCw
data were parsed by histogram analyses. Our results
indicate that DW-MRI can be used for early detection of
prostate carcinoma xenograft response to docetaxel
chemotherapy.
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Introduction
Prostate cancer is the most commonly diagnosed cancer and
the second leading cause of cancer death in American men.
An estimated 39,200 men die of prostate cancer in the US
annually [1 ]. In nearly all patients, growth and progression of
cancer occur despite initial androgen ablation therapy [2].
Although the occurrence of prostate cancer is rare before age
40, the prevalence of the disease quickly increases to 80% by
the age of 80. In 1941, Huggins et al. [3 ] showed that bilateral
orchiectomy induced acute biochemical and clinical improve-
ment in 80% of men with metastatic prostate cancer.
However, this response to androgen ablation therapy was
temporary, with a median response duration of 12 to 16
months [4,5 ]. With increasing life expectancy, hormone-
refractory prostate cancer (HRPC) represents the most
common form of male cancer in the US and other Western
countries [6]. The population of early ‘‘geriatric’’ HRPC
patients is rapidly increasing, posing an even greater
challenge to oncologists treating this difficult - to-manage
disease.
The evolution of early prostate cancer is unpredictable
and may extend over many years. Some tumors progress
rapidly and become fatal within a few years. Other tumors
may advance slowly, or not at all. A commonly held opinion
is that chemotherapy plays a limited role in the treatment of
prostate cancer because no single agent or combination of
agents has been shown to prolong survival in randomized
trials. However, this point of view may be changing.
Preliminary findings of in vitro experiments have challenged
traditional beliefs that prostate cancers are resistant to
chemotherapy [7]. Recent clinical trials using taxanes as
monotherapy have provided promising results [8,9 ]. In the
treatment of prostate cancer, various interventions that are
rapidly evolving combine chemotherapy with traditional
therapies (e.g., hormonal and radiation), or use chemo-
therapy in conjunction with a variety of investigational
approaches [10].
Docetaxel belongs to the taxoid family, a class of
antineoplastic drugs useful in the treatment of several types
of cancers such as breast, ovarian, and non–small cell lung
cancer. Docetaxel was derived from the convergent syn-
thesis of paclitaxel, which has been effective in treating
breast cancer for more than 4 years. Docetaxel arrests tumor
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growth via cytostatic and cytotoxic mechanisms. It works by
stabilizing microtubules, preventing mitosis, and ultimately
inducing apoptosis or necrosis [11-14]. Both paclitaxel and
docetaxel bind to specific sites on tubulin subunits to stabilize
the polymerized filaments, although docetaxel binds to
tubulin with twice the affinity of paclitaxel [15].
Once a treatment regimen has been designed, close
monitoring of tumor response to therapy becomes essential.
Currently, prostate tumor response to therapy is monitored
by frank radiographic changes in tumor morphology and
serum levels of prostate-specific antigen (PSA). PSA is an
excreted protease that is expressed both by normal and
malignant prostatic epithelium. Normal basalar levels are
about 4 ng/ml, and in patients with prostate carcinoma,
serum PSA levels are generally higher, about 10 ng/ml [16].
Although most studies valuate the cutoff for normal serum
PSA levels at about 4 ng/ml, 20% of cancers are not
detected ( false-negative) and 65% of patients with benign
disease are made to undergo further testing ( false-
positive), making the positive predictive value of a PSA
>4.0 ng/ml only about 25% [17,18]. It appears that this low
sensitivity /specificity is due to the inability of current
immunotechniques to distinguish between early prostate
cancer and benign prostatic hyperplasia. Recently, studies
have increased the specificity and sensitivity values (90%
and 50%, respectively ) of PSA testing simply by determining
the free PSA (as compared to total PSA or PSA density) in
the blood at a cutoff of 30% [19]. In general, changes in
tumor morphology and serum PSA are clinically useful, but
changes in these parameters may take weeks or months to
become evident.
Several magnetic resonance imaging (MRI) modalities
have been employed for the early detection of therapy
response in various cancer models. Clinical trials have
evinced the utility of T2-weighted imaging to monitor
therapeutic response in a pancreatic tumor model [20],
and T1(rho) imaging ( in conjunction with other modalities)
has been used to assess treatment planning in brain tumors
[21]. Dynamic contrast -enhanced (DCE) MRI measures the
rate of enhancement on a pixel -by-pixel basis using T1-
weighted imaging following a bolus injection of gadolinium-
based contrast agents, and DCE-MRI has been used both
clinically and preclinically to monitor response to cytotoxic
and cytostatic therapies [22]. Additionally, 1H magnetic
resonance spectroscopy has been used to detect changes in
tumor lactate levels as an early indicator of radiosensitive
RIF-1 tumor response to radiation therapy [23].
A novel indicator of tumor response to therapy is the
apparent diffusion coefficient of water (ADCw) as measured
by diffusion-weighted (DW) MRI. In preclinical models,
DW-MRI can detect tumor response to chemotherapy
quantitatively, sensitively, and early in the treatment
regimen [24-31]. Although the exact mechanisms under-
lying changes in ADCw following therapy are unknown, it is
hypothesized that the increased ADCw is reflecting a
decreased intracellular volume fraction caused by apopto-
sis-associated cell shrinkage, necrosis, or vasogenic ede-
ma. Because water is not as diffusionally restricted in the
extracellular space, compared to the intracellular, a
decrease in cell volume fraction will result in an overall
increase in the ADCw [28]. In the current study, we
investigated the response of the tumor ADCw to a novel
drug, docetaxel, in a novel tumor type, LnCaP. Docetaxel
was chosen because it is cytostatic at low doses and
cytotoxic at higher doses (unpublished observations). The
LnCaP cell line was chosen because it secretes PSA.
Serum PSA levels and tumor volumes were used to
noninvasively measure tumor response. Although there
are additional and more specific markers of prostate cancer,
such as DD3 and membrane-associated PSA [32], serum
PSA was used in this case because repeated and non-
invasive measurements could be performed on the same
mouse.
Materials and Methods
Cell Lines and Tumors
LnCaP, a tumorigenic cell line originally derived from a
lymph node metastasis of a human prostatic adenocarci-
noma, was obtained from the American Type Culture
Collection (CRL 1740; Rockville, MD). Passages were made
twice weekly with a 1:2 split and cultured in DMEM:F12
supplemented with 10% FBS (HyClone, Ft. Collins, CO). For
inoculation, approximately 4106 cells in 2.6 ml of media
were suspended in 2.4 ml of Matrigel (Becton Dickinson
Labware, Bedford, MA) and injected subcutaneously into the
right flanks of SCIDmice. SCIDmice are severely deficient in
T and B cells and fail to reject allogeneic grafts or produce
antibodies to common antigens, including PSA. Several
human tumor xenografts have been grown in SCID mice and
effectively treated with chemotherapy [33,34]. Male SCID
mice of ages 5 to 6 weeks were obtained from the Arizona
Cancer Center Experimental Mouse Shared Services.
Measurement of Tumor Response
Most mice developed palpable tumors within 2 to 3 weeks
of inoculation. At the time of chemotherapeutic treatment and
imaging, tumor volumes ranged from 75 to 975 mm3. Tumor
volumes were measured using standard calipers and
calculated as ( lengthwidth2) /2, with the length and width
defined as the long and short axes, respectively. Blood
samples of 100 to 200 L were obtained from each mouse
from the retro-orbital plexus using capillary tubes: samples
were collected twice monthly until tumor volume was
measurable, once per week thereafter, and at 0, 2, 4, 6, 8,
and 15 days following commencement of treatment. The
whole blood samples were stored at 808C pending
analysis. The samples were analyzed via enzyme- linked
immunosorbent assay (ELISA; C. Hamlin, CWRU, Cleve-
land, OH) to determine serum PSA levels.
MRI
MRI experiments were initiated on a mouse when the
tumor size was between 220 and 800 mm3. The chemo-
therapy was fractionated and synchronized with imaging as
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follows. Both imaging and therapy commenced with half the
cumulative dose on day 0. Mice were imaged again on
days 2 and 4. On days 4 and 6, mice were treated with one
fourth the cumulative dose of chemotherapy. All MRI
experiments were carried out on a 40-cm horizontal bore
Bruker Biospec Avance 4.7-T imaging spectrometer
(Bruker, Karlsuhe, Germany) equipped with an actively
shielded gradient coil capable of 150 mT/m. Mice were
anesthesized with 1.5% isoflurane delivered in O2, at 1.0 l /
min, and placed in a homebuilt probe that allowed
positioning of the tumor within a 1-cm-diameter, two- turn
solenoid coil. Animal temperatures were continuously
monitored using a rectal Luxtron fluoroptic thermometer
(Luxtron, Santa Clara, CA). A recirculating water - filled
heating pad was used to maintain core body temperature
between 368C and 378C during the course of the imaging
experiments.
Sagittal scout images were obtained to determine the
position and extent of tumors. DW-MRI was then carried out
using 2-mm-thick coronal slices covering the entire tumor
volume. A diffusion-weighted radial acquisition of data
(DIFRAD) method was employed [35]. Typical acquisition
parameters were: TR=1300 to 2000 ms (depending on the
number of slices), TE=50.00 ms, FOV=3.843.84 cm,
matrix size=128128, slice thickness=2.00 mm (contigu-
ous), =20.00 ms, @=7.00 ms, where @ and  represent
duration and separation of diffusion gradients, respectively.
Three orthogonal diffusion gradient directions were
employed. At each slice location, images were obtained at
three b values [b= 2Gd
2@ 2(@ /3) ], where Gd is the
strength of the diffusion weighting gradient and  is the
gyromagnetic ratio for protons (42.58 MHz/T).Images were
reconstructed from the radial data using a magnitude filtered
back projection algorithm, which minimizes artifacts due to
motion [35]. Apparent diffusion coefficient (ADCw) maps
were generated by fitting the signal intensity of each pixel to a
single exponential decay:
S ¼ S0ebADCw
where S0 is the signal intensity in the absence of diffusion
weighting, and S is the signal intensity with diffusion
weighting. ADCw maps were analyzed using programs
written in Interactive Data Language (Research Systems,
Boulder, CO). Regions of interest (ROIs) corresponding to
tumor were drawn on the ADCw maps, and ADCw distribution
histograms were obtained for each tumor from each imaging
session (days 0, 2 and 4). The same person defined all ROIs
in order to minimize interoperator error, and hence, max-
imize precision.
Chemotherapy
Docetaxel was obtained from spent clinical doses, stored
at 258C for up to 2 weeks prior to use. Dosage limits were
determined in control non–tumor-bearing SCID mice
treated with single doses of 40, 60, 80, and 100 mg/kg
docetaxel. The highest dosages, 80 and 100 mg/kg, were
lethal. Hence, the maximum tolerated single dose was
established at 60 mg/kg. Total doses administered ranged
from 0 to 60 mg/kg, delivered in three fractions of 0.5, 0.25,
and 0.25 total dose on days 0, 4, and 6, respectively. This
dosing scheme was chosen to avoid redosing animals
during the imaging schedule, which occurred on days 0, 2
and 4.
Results
Tumor Response
Independent measurements of tumor volume and PSA
levels were used to characterize tumor response following
Figure 1. Tumor volumes and serum PSA levels following docetaxel therapy.
( a ) Tumor volumes were measured by palpation using calipers ( the descrip-
tion of calculations can be found in Materials and Methods section ). The graph
is an example of an individual tumor volume plot, which follows the prog-
ression, as well as regression, of the tumor over time. Line (1 ) shows the least
squares fit of pretreatment volume data points, and line ( 2 ) shows the least
squares fit of volume data points during regrowth. The x - axis projections of
the linear regressions during initial growth and regrowth were used to
determine the TGD. (Arrows ) Represent days 32, 36, and 38 on which
animals received treatment with docetaxel of the indicated doses in milligrams
per kilogram. ( b ) This representative plot follows the serum PSA levels over
time. Blood serum samples were collected from the orbital plexus at each
recorded data point, and levels of the serum PSA were analyzed by ELISA
(Materials andMethods section ). (Arrows ) Represent the days 32, 36, and 38
on which animals received treatment with docetaxel of the indicated doses in
units of milligrams per kilogram. Note the rapid decline in levels of PSA
following the initial dose, providing illustration that PSA levels are a more
sensitive indication of change than tumor volume measurements in (a ) of
same mouse.
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chemotherapy. A conventional indicator of response, tumor
growth delay (TGD), measures the time it takes for tumors to
regrow to pretreatment volumes following chemotherapy
[36]. Figure 1a shows an example of a typical tumor volume
plot along with calculation of TGD. Changes in serum PSA
levels for individual mice were plotted against time, as shown
in Figure 1b, demonstrating that serum PSA levels provided
an adequate biomarker for the progression and response of
prostate tumors. Figure 2a illustrates the strong correlation
between the PSA levels and tumor volumes before treatment
( r 2=0.90). Figure 2b demonstrates that within the range of 6
to 24 days following commencement of therapy, this
correlation was reduced, and levels of PSA no longer
correlated with caliper -measured tumor volumes. These
data can be interpreted to indicate that, following therapy,
there is a reduction in PSA production without a concomitant
decrease in tumor volumes.
Dose Response to Docetaxel
Figure 3a shows a strong dose response of the average
TGD. In some cases, TGD information was not available.
Several mice expired after imaging, but before tumor
regrowth occurred. Consequently, the percent tumor volume
remaining by day 25 was used as an alternative measure of
response. As shown in Figure 3b, the ratio of the average
tumor volume remaining on day 25 relative to day 0 ( i.e., 25
days posttreatment) decreased as the dose increased. The
average tumor volume remaining at 0, 10, 30, and 60 mg/kg
docetaxel was 1.0, 0.84 (P=.08), 0.54 (P<.05), and 0.22
(P0.001), respectively. Because PSA production failed to
recover in all tumors, the percent level of PSA remaining by
day 18 relative to day 0 was also used as a measure of
response. At 60 mg/kg docetaxel, serum PSA levels
dropped to 24.5±8.1% of the levels recorded on day 0
(P<.05). In untreated mice, average PSA levels increased
by greater than 20- fold (P<.001) over this time (18d).
Diffusion Response
Preliminary diffusion tensor imaging showed no appreci-
able diffusion anisotropy, and it was reasonably assumed
that diffusion within the LnCaP tumor model is isotropic (data
not shown). Nonetheless, three diffusion gradient directions
were used to acquire data, and averaged to obtain isotropic
diffusion coefficients. DW-MRI were obtained at three b
values of 200, 400, and 800 sec/mm2, as shown in Figure
4a  c. ADCw maps were generated from these images as
described above and shown in Figures 4d and 5. Repro-
ducibility of these ADCw measurements was determined by
Figure 2. Correlations between tumor volume changes and serum PSA
levels pre - and post - therapy. ( a ) Illustrates a significant correlation between
caliper -measured tumor volume data and serum PSA levels before treatment
( n=6 ). ( b ) Demonstrates that following chemotherapy, the correlation
between the tumor volume and PSA levels is reduced (n=5 ).
Figure 3. Demonstration of the changes in parameters following treatment.
( a ) Illustrates the average TGD calculated for mice at corresponding
treatments with docetaxel. ( b ) Illustrates the ratio of the average tumor
volume remaining on day 25 relative to day 0 ( i.e., 25 days post - treatment ) at
corresponding doses of docetaxel.
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the acquisition of repeated data sets from the same animal in
the same session, wherein the animal was removed from the
magnet and repositioned between acquisitions. From these
measurements, we determined that the reproducibility of
mean ADCw values were ±0.88%, ±4.28%, and ±2.7% on
days 0, 2, and 4, respectively. Hence, changes in the ADCw
greater than 5.16% and 3.58% on days 2 and 4 (relative to
day 0) are significant ( i.e., greater than 2 SD). Figure 5 also
illustrates the effect of docetaxel on the ADCw of a
responding tumor. As treatment is initiated, the majority of
pixels in an ADCw map have low ADCw values (approx-
imately 0.2 to 0.6103 mm2/sec, shown in green). As
treatment progresses, there is a shift to higher ADCw values
(0.8 to 1.7103 mm2/sec, shown in red and yellow).
During imaging, variable tumor volumes necessitated a
variable number of acquisition slices (usually four to six
slices). As mentioned in Materials and Methods section, raw
data acquired from the ADCw map of each tumor volume
slice were analyzed and assembled into histograms that
plotted the pixel frequency at different ADCw values. Histo-
grams from each slice were compiled to generate one
inclusive histogram, which represented the total tumor
Figure 4. Calculation of the ADCw from a series of diffusion -weighted images. Four diffusion -weighted images were obtained at different b values: ( a ) b=200, (b )
b=400, and (c ) b=800 sec /mm2. For illustrative purposes, a ROI of 25 pixels was defined on each diffusion -weighted image, and the mean signal intensity of this
region for each b value is fitted to the single exponential decay shown in the graph. A similar fit was performed on a pixel - by - pixel basis to generate the ADCw map
shown in (d ).
Figure 5. Tumor ADCwmaps obtained frommouse treated at 60 mg /kg docetaxel. Images were acquired and processed as described in text. The ADCwmaps were
obtained on different days, and although these data were approximately of the same imaging slice, registration of these images is not implied. Reproducibility was
±0.88%, ±4.28%, and ±2.72% on days 0, 2, and 4, respectively.
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volume. Example histograms before and after treatment are
shown in Figure 6b. In addition, there were significant linear
correlations between the total number of pixels in each total
tumor volume histogram and the caliper measurements of
their corresponding tumor volumes before and after treat-
ment ( r 2=0.85 and 0.83, respectively).
Changes in the mean ADCw values following treatment
are shown in Figure 7. The ratio of the mean ADCw
measured on days 2 and 4 with the mean ADCw measured
before treatment (day 0) is plotted versus dose. For
animals receiving no treatment (0 mg/kg), the ADCw
decreased by day 2, with a greater decrease by day 4,
indicating that a decrease in ADCw accompanies stable
tumor growth (P<.1). However, no significant correlation
was observed between tumor size and ADCw values (data
not shown). For doses of 10 to 60 mg/kg docetaxel, the
mean ADCw increased on days 2 and 4 (P=0.03 and
P<0.01, respectively). From these data, it is concluded that
an early increase in the mean ADCw was indicative of tumor
response to chemotherapy.
Discussion
These data illustrate that docetaxel is effective in treating
xenografts of prostate adenocarcinoma, and that the
changes in the ADCw as measured by DW-MRI are an
earlier indicator of response than tumor volume or serum
PSA level. Of the mice enrolled in this study, only one
animal was nonresponsive to the docetaxel chemotherapy.
Significant growth delays and reductions in serum PSA
were observed at all doses >10 mg/kg. Serum PSA levels
also declined early in the treatment regimen indicating that,
in this model, the decline in serum PSA may be used as an
early marker for therapeutic response. Because LnCaP is
one of few PSA-secreting prostate cancer cell lines
available, this phenomenon is unique to this tumor
xenograft system. In humans, PSA is secreted by stromal,
as well as tumor, cells. Hence, the use of PSA as an early
response indicator in a clinical setting is not robust (vide
supra ). Another interesting observation was the discord-
ance between the serum PSA levels and tumor volumes
posttherapy, as shown in Figure 2b. These data can be
interpreted to indicate that, in response to therapy, PSA
production, which presumably requires healthy and well -
energized cells, is a more sensitive indicator of response
than is tumor volume. Moreover, the relative lack of re-
duction in tumor volume might be due to lack of macro-
phage clearance of cell debris. In other systems, it has been
shown that tumor volume measurements systematically
Figure 7. Demonstration of changes in ADCw following treatment. The ratio of
the mean ADCw values on day 2 (dashed line ) and day 4 ( solid line ) relative to
day 0 is shown at specified doses. The 95% confidence belts are shown as
dotted lines. Hence, the ADCw of all untreated controls decreases significantly
on days 2 and 4, whereas treated animals show significant increases only on
day 4. The ADCw values for all treated animals were significantly higher than
untreated controls on both days 2 and 4.
Figure 6. ADCw histogram plot. From the diffusion maps, ADCw histograms
were generated by plotting the pixel density against a corresponding ADCw
value. From these histograms, the mean and median values were calculated.
It was expected that a right shift in the ADCw mean value ( as indicated by the
solid line ) would be greater at post - treatment, concomitant with a greater
diffusion within the tumor following induction of cell death. The above
histogram demonstrates a typical right shift in the ADCw value of total tumor
volume following chemotherapy.
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underestimate cell kill and that this underestimation may be
due to an accumulation of dead cells within the residual
tumor volume following treatment [37]. It has also been
hypothesized that such disparities between cell kill and
tumor volume estimations may be linked to cellular swelling
or extracellular edema [38]. Because tumors were not
imaged by DW-MRI at later time points, it is unclear
whether there are large edematous or necrotic regions that
occupy volume but do not produce PSA.
Increases in the ADCw were observed at all doses of
docetaxel. According to the current treatment protocol,
animals receiving docetaxel doses of 10 mg/kg actually
received 5 mg/kg, or half the total dose, prior to imaging. At
these doses, there are significant increases in the mean
ADCw within 2 days following commencement of therapy.
This same group had less significant decreases in PSA and
tumor volumes by 18 to 25 days posttreatment. This
suggests that, although the changes in ADCw of tumors
are presumably reporting changes in tumor physiology and
microenvironment, these changes may not be intimately
coupled to therapeutic response. A current hypothesis states
that these changes are reporting damage to the tumor
physiology from which the cells may recover. Hence, these
changes may be used to optimize timing of fractionated
chemotherapy such that subsequent doses may be applied
when the tumor is most vulnerable ( i.e., at its highest ADCw
value).
In a clinical setting, the utility of an early response
indicator is limited to its strength in predicting the response of
individual tumors in individual patients. Clinical trials are
ongoing to assess the applicability of ADCw as an early
response predictor in brain tumors [39,40], metastatic
lymphomas (G. Gonzales, Massachusetts General Hospital,
personal communication), and metastatic breast cancer
lesions in the liver [unpublished observation ]. In the current
project, the lack of correlation between the TGD and PSA
data precludes testing of the hypothesis that early ADCw
changes can predict response in individual tumors (Gillies et
al., in preparation).
Acknowledgements
The authors would like to thank C. Hamlin (Case Western
Reserve University, Cleveland, OH) for the PSA measure-
ments, Brenda Baggett for cell culture, and Merry Warner for
organizational support.
References
[1] Landis SH, Murray T, Bolden S, and Wingo PA (1998). Cancer statistic,
1998. CA Cancer J Clin 48, 6–29.
[2] Oh WK, and Kantoff PW (1998). Management of hormone - refractory
prostate cancer: current standards and future trends. J Urol 160, 1220–
29.
[3] Huggins C, Stevens RE, and Hodges CV (1941). Studies on prostate
cancer: II. The effects of castration on advanced carcinoma of the
prostate gland. Arch Surg 43, 209.
[4] Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R,
Dorr FA, Blumenstein BA, Davis MA, and Goodman PJ (1989). A
controlled trial of leuprolide with and without flutamide in prostatic
carcinoma. N Engl J Med 321, 419–24.
[5] Raghavan D (1988). Non -hormone chemotherapy for prostate cancer:
principles of treatment and application to the testing of new drugs.
Semin Oncol 15, 371–89.
[6] Beedassy A, and Cardi G (1999). Chemotherapy in advanced prostate
cancer. Semin Oncol 26, 428–38.
[7] Kuyu H, Lee WR, Bare R, Hall MC, and Torti FM (1999). Recent
advances in the treatment of prostate cancer. Ann Oncol 10, 891–98.
[8] Picus J, and Schultz M (1999). Docetaxel (Taxotere ) as monotherapy
in the treatment of hormone - refractory prostate cancer: preliminary
results. Semin Oncol 26, 14–18.
[9] Smith DC, and Pienta KJ (1999). Paclitaxel in the treatment of
hormone - refractory prostate cancer. Semin Oncol 26, 109–11.
[10] Small EJ, Reese DM, and Vogelzang NJ (1999). Hormone - refractory
prostate cancer: an evolving standard of care. Semin Oncol 26,
61–67.
[11] Millenbaugh NJ, Gan Y, and Au JL (1998). Cytostatic and apoptotic
effects of paclitaxel in human ovarian tumors. Pharm Res 15, 122–27.
[12] Gan Y, Wientjes MG, Lu J, and Au JL (1998). Cytostatic and apoptotic
effects of paclitaxel in human breast tumors. Cancer Chemother
Pharmacol 42, 177–82.
[13] Lanzi C, Cassinelli G, Cuccuru G, Supino R, Zuco V, Ferlini C,
Scambia G, Zunino F (2001). Cell cycle checkpoint efficiency and
cellular response to paclitaxel in prostate cancer cells. Prostate 48,
254–64.
[14] Wang LG, Liu XM, Kreis W, and Budman DR (1999). The effect of anti -
microtubule agents on signal transduction pathways of apoptosis: a
review. Cancer Chemother Pharmacol 44, 355–61.
[15] Stein CA (1999). Mechanisms of action of taxanes in prostate cancer.
Sem Oncol 26, 3–7.
[16] Atalay AC, Karaman MI, Guney S, Dalkilic A, Muslumanoglu AY, and
Ergenekon E (1998). Age - specific PSA reference ranges in a group of
non -urologic patients. Int Urol Nephrol 30, 587–91.
[17] Beduschi MC, and Oesterling JE (1998). Percent free prostate - specific
antigen: the next frontier in prostate - specific antigen testing. Urology
51, 98–109.
[18] Fritsche HA. In: Balzac F (Ed ). Complexed PSA: A New Mar-
ker for Prostate Cancer Walton, CT. <http: //www.labnews.com /
guest_speakers / Fritsche.shtml>.
[19] Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman
CC, and Marberger M (2000). Optimal predictors of prostate cancer on
repeat prostate biopsy: a prospective study of 1,051 men. J Urol 163,
1144–48.
[20] He Z, Evelhoch JL, Mohammad RM, Adsay NV, Pettit GR, Vaitkevicius
VK, and Sarkar FH (2000). Magnetic resonance imaging to measure
therapeutic response using an orthotopic model of human pancreatic
cancer. Pancreas 21, 69–76.
[21] Poptani H, Duvvuri U, Miller CG, Mancuso A, Charagundla S, Frase
NW, Glickson JD, Leigh JS, and Reddy R (2001). T1 rho imaging of
murine brain tumors at 4T. Acad Radiol 8, 42–47.
[22] Mardor Y, Roth Y, Lidar Z, Jonas T, Pfeffer R, Maier SE, Faibel M, Nass
D, Hadani M, Orenstein A, Cohen JS, and Ram Z (2001). Monitoring
response to convection— enhance Taxol delivery in brain tumor
patients using diffusion -weighted magnetic resonance imaging. Cancer
Res 61, 4971–73.
[23] Aboagye EO, Bhujwalla ZM, He Q, and Glickson JD (1998). Evaluation
of lactate as a 1H nuclear magnetic resonance spectroscopy index for
noninvasive prediction and early detection of tumor response to
radiation therapy in EMT6 tumors. Radiat Res 150, 38–42.
[24] Kim B, Chenevert TL, and Ross BD (1995). Growth kinetics and
treatment response of the intracerebral rat 9L brain tumor model: a
quantitative in vivo study using magnetic resonance imaging. Clin
Cancer Res 1, 643–50.
[25] Zhao M, Pipe JG, Bonnett J, and Evelhoch JL (1996). Early detection of
treatment response by diffusion -weighted 1H -NMR spectroscopy in
murine tumors in vivo. Br J Cancer 73, 61–64.
[26] Chenevert TL, McKeever PE, and Ross BD (1997). Monitoring early
response of experimental brain tumor therapy using diffusion magnetic
resonance imaging. Clin Cancer Res 3, 1457–66.
[27] Poptani H, Puumalainen AM, Grohn OH, Loimas S, Kainulainen R,
Yla -Herttuala S, and Kauppinen TA (1998). Monitoring thymidine
kinase and ganciclovir - induced changes in rat malignant glioma in
vivo by nuclear magnetic resonance imaging. Cancer Gene Ther 5,
101–109.
[28] Galons JP, Altbach MI, Paine -Murrieta GD, Taylor CW, and Gillies RJ
(1999). Early increases in breast tumor xenograft water mobility in
response to paclitaxel therapy by non - invasive diffusion magnetic
resonance imaging. Neoplasia 1, 113–17.
Neoplasia . Vol. 4, No. 3, 2002
Response of Xenografts to Docetaxel Jennings et al. 261
[29] Gillies RJ, Bhujwalla ZM, Evelhoch J, Garwood M, Neeman M,
Robinson SP, Sotak CH, and Van Der Sanden B (2000). Applications
of magnetic resonance in model systems: tumor biology and
physiology. Neoplasia 2, 139–51.
[30] Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ,
Nalcioglu O, Raghunand NR, Ronen SM, Ross BD, and Swartz HM
(2000). Applications of magnetic resonance in model systems: cancer
therapeutics. Neoplasia 2, 152–65.
[31] Stegman LD, Rehemtulla A, Hamstra DA, Rice DJ, Jonas SJ, Stout KL,
Chenevert TL, and Ross BD (2000). Diffusion MRI detects early events
in the response of a glioma model to the yeast cytosine deaminase
gene therapy strategy. Gene Ther 7, 1005–10.
[32] Bussemakers MJG, van Bokhoven A, Verhaegh GW, Smit FP,
Harthaus HFM, Schalken JA, Debruyne FMJ, Ru N, and Isaacs WB
(1999). DD3: a new prostate - specific gene, highly overexpressed in
prostate cancer. Cancer Res 59, 5975–79.
[33] Paine -Murrieta GD, Taylor CW, Curtis RA, Lopez MH, Dorr RT,
Johnson CS, Funk CY, Thompson F, and Hersh EM (1997). Human
tumor models in the severe combined immune deficient (SCID ) mouse.
Cancer Chemother Pharmacol 40, 209–14.
[34] Taetle R, Rosen F, Abramson I, Venditti J, and Howell S (1987). Use of
nude mouse xenografts as pre - clinical drug screens: in vivo activity of
established chemotherapeutic agents against melanoma and ovarian
xenografts. Cancer Treat Rep 71, 297–304.
[35] Trouard TP, Theilmann RJ, Altbach MI, and Gmitro AF (1999). High -
resolution diffusion imaging with DIFRAD -FSE (diffusion -weighted
radial acquisition of data with fast spin - echo ) MRI. Magn Res Med 42,
11–18.
[36] Raghunand N, Mahoney B, Van Sluis R, Baggett B, and Gillies RJ
(2001). Acute metabolic alkalosis enhances response of C3H mouse
mammary tumors to the weak -base mitoxantrone. Neoplasia 3,
227–35.
[37] Ross BD, Zhao YJ, Neal ER, Stegman LD, Ercolani M, Ben -Yoseph
O, and Chenevert TL (1998). Contributions of cell kill and post -
treatment tumor growth rates to the repopulation of intracerebral 9L
tumors after chemotherapy: an MRI study. Proc Natl Acad Sci 95,
7012–17.
[38] Weizsaecker M, Deen DF, Rosenblum ML, Hoshino T, Gutin PH, and
Barker M (1981). The 9L rat brain tumor: description and application of
an animal model. J Neurol 224, 183–92.
[39] Chenevert TL, Stegman LD, Taylor JMG, Robertson PL, Greenberg
HS, Rehemtulla A, and Ross BD (2000). Diffusion magnetic resonance
imaging: an early surrogate marker of therapeutic efficacy in brain
tumors. J Natl Cancer Inst 92, 2029–36.
[40] Mardor Y, Tichler T, Roth Y, Weiss Y, Berger R, Glicksman A, Pfeffer
R, Spiegelman R, Ruiz -Cabello J, Maier SE, Orenstein A, and Cohen J
(2001). Early prediction of tumor response to therapy using diffusion -
weighted MRI. Proc Intl Soc Magn Res. 9: Abstract 2269.
262 Response of Xenografts to Docetaxel Jennings et al.
Neoplasia . Vol. 4, No. 3, 2002
